Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.
about
Pharmacogenetics of treatment response in psoriatic arthritisCardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritisFolic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritisEstimation of haplotype frequencies, linkage-disequilibrium measures, and combination of haplotype copies in each pool by use of pooled DNA data.Test of association between haplotypes and phenotypes in case-control studies: examination of validity of the application of an algorithm for samples from cohort or clinical trials to case-control samples using simulated and real data.Association of MTHFR gene polymorphisms with breast cancer survival.Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population.Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.Leveraging human genetics to develop future therapeutic strategies in rheumatoid arthritisAJG series: molecular biology for clinicians.Large-scale single-nucleotide polymorphism (SNP) and haplotype analyses, using dense SNP Maps, of 199 drug-related genes in 752 subjects: the analysis of the association between uncommon SNPs within haplotype blocks and the haplotypes constructed wiPharmacogenetics and pharmacogenomics in rheumatology.Geographical and ethnic distribution of single nucleotide polymorphisms within genes of the folate/homocysteine pathway metabolismGenetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammationPharmacogenetics in the rheumatic diseasesPharmacogenetics in clinical practice: considerations for testing.Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis.Role of the MTHFR polymorphisms in cancer risk modification and treatment.Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritisEffect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexedPhase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancerThe Frequency of A1298C and C677T Polymorphisms of the Methylentetrahydrofolate Gene in Turkish Patients with Rheumatoid Arthritis: Relationship with Methotrexate Toxicity.Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR geneRacial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.Pharmacogenetic approaches to rheumatoid arthritis.Pharmacogenomics and stomach cancer.Pharmacogenetics of methotrexate.Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology.The Impact of Methylenetetrahydrofolate Reductase C677T Polymorphism on Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Methotrexate ProphylaxisAdversomics: a new paradigm for vaccine safety and design.The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.Methotrexate pharmacogenomics.Clinical application of pharmacogenetics in gastrointestinal diseases.Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy.Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.Psoriatic arthritis: genetic susceptibility and pharmacogenetics.
P2860
Q28081252-4E72C02D-29D0-4010-892E-0142A6D204CAQ28390163-5BDC634D-66D3-44A5-9125-CA905EA2CDB7Q28394552-B06BA441-2061-41E7-A782-C104BD8D1663Q30762288-95871B59-ECDF-4013-832E-28C1FFCFD2CEQ31061304-328D52B8-1241-427E-9997-DD94595885A0Q33261851-4C92CE11-FAE9-476F-9240-A95F2E4E999DQ33395136-8209DB17-FBE3-4A57-9855-851EC1573161Q33747444-BC4A7083-9BD1-4F08-B570-5C372FF66F90Q33888733-765B4A0A-E53E-4DD7-99F3-76C2A65042B8Q33984210-B59C99DA-E58C-4815-8AAD-668E758C2B03Q33998500-2E9795FE-2932-4648-9FB3-D070DEE16741Q34070615-BE45450D-3E4C-4C03-A087-A1A9A060CEA3Q34232715-57D50200-AF84-4E0B-B3B3-C6DDC4030FE2Q34293811-0088ACEF-8F32-4A31-9297-B9A56FB93C1EQ34358310-CD7F506C-003F-44E0-896A-929F5BAD09FBQ34499056-B50C8EE0-9DAB-4985-9C94-3CC59DB1E782Q34559803-B6B498F7-35B3-44E9-9EF8-5FA7AC41BF61Q34580608-DD3C837E-B28F-4226-9649-4F7E88212A22Q34658549-5CEE0BB0-BB9C-4134-B1CE-F1A0C61F2D54Q35024962-6AFE1D73-26A1-4E20-A636-421CC9D6A478Q35134668-D04B38CE-6E1A-40F6-A9D2-294B8E867139Q35179998-AE66CCFD-B199-4069-8E71-4315BFF74496Q35432484-D7765E06-8BFC-410C-AF1E-33E6BC60F6EEQ35480214-42F71D1C-02E3-4C0D-A510-875D35976590Q35553306-B2A99DCA-18C0-4411-A63E-A68625F296DCQ35637808-F27C4677-4853-45D6-AACD-4677A04E1A9AQ35834289-176E429B-CA0F-42D4-94C9-5A0F08ADA7E5Q35873676-6EC8181D-1D14-4445-AE6D-96D6BEB702A6Q35911142-4DC4C838-0C65-438E-A620-ED6669BD4235Q35976402-21083AA5-C413-428B-B325-83226699B492Q36175130-C2C9B73A-1CA3-4917-9D92-B01ECD54A751Q36242667-6F4B0CD7-56C5-415F-8F59-49FB0F71CEFBQ36286418-F22966CB-AC0B-4923-9BA3-54DE98973B67Q36441438-57B63C93-7C22-4B01-BB77-1948B8533CEAQ36564583-86F6E6C6-7846-4DC2-B228-9A3137B7DDA1Q36613862-6AA4A7BB-BB0A-46D7-ACF0-09AEED19C462Q36642796-61CC1B34-011C-4316-9D11-686ACB03BDF9Q36774217-84127C25-7A92-470B-8362-14D0A4954D60Q37012007-8F5D91D8-297B-4D80-8A8E-BA402E5DB913Q37120837-09F8A5B0-A3BE-4FE5-BF8F-085D85A640D8
P2860
Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Polymorphisms in the methylene ...... locus and haplotype analyses.
@en
Polymorphisms in the methylene ...... locus and haplotype analyses.
@nl
type
label
Polymorphisms in the methylene ...... locus and haplotype analyses.
@en
Polymorphisms in the methylene ...... locus and haplotype analyses.
@nl
prefLabel
Polymorphisms in the methylene ...... locus and haplotype analyses.
@en
Polymorphisms in the methylene ...... locus and haplotype analyses.
@nl
P2093
P1476
Polymorphisms in the methylene ...... locus and haplotype analyses.
@en
P2093
Atsuo Taniguchi
Eiichi Tanaka
Hideto Akama
Hiroshi Nakajima
Hisashi Yamanaka
Naoyuki Kamatani
Wako Urano
Yuko Matsuda
Yutaka Kitamura
P304
P356
10.1097/00008571-200204000-00002
P577
2002-04-01T00:00:00Z